Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials
出版年份 2019 全文链接
标题
Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials
作者
关键词
-
出版物
Cancers
Volume 11, Issue 12, Pages 1826
出版商
MDPI AG
发表日期
2019-11-21
DOI
10.3390/cancers11121826
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
- (2019) Gabriel Rinnerthaler et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Near-Infrared Photoimmunotherapy of Cancer
- (2019) Hisataka Kobayashi et al. ACCOUNTS OF CHEMICAL RESEARCH
- CAR-T Engineering: Optimizing Signal Transduction and Effector Mechanisms
- (2019) Emiliano Roselli et al. BIODRUGS
- Treatment of advanced HER2-positive breast cancer: 2018 and beyond
- (2018) Noam Pondé et al. CANCER TREATMENT REVIEWS
- Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses
- (2018) Jang Hwan Cho et al. CELL
- STAT3 and apoptosis challenges in cancer
- (2018) Nazanin Fathi et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Structural insights into the mechanism of action of a biparatopic anti-HER2 antibody
- (2018) Vaheh Oganesyan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Mechanisms of receptor tyrosine kinase activation in cancer
- (2018) Zhenfang Du et al. Molecular Cancer
- Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors
- (2018) Wagner Ricardo Montor et al. Molecular Cancer
- Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines
- (2018) Ines De Pauw et al. Molecular Oncology
- Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer
- (2018) Nikolaos Zacharakis et al. NATURE MEDICINE
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer
- (2018) Lei Wang et al. CANCER SCIENCE
- HER2-positive breast cancer
- (2017) Sibylle Loibl et al. LANCET
- 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
- (2017) David Cameron et al. LANCET
- Emerging functions of the EGFR in cancer
- (2017) Sara Sigismund et al. Molecular Oncology
- Engineering Natural Killer Cells for Cancer Immunotherapy
- (2017) Katayoun Rezvani et al. MOLECULAR THERAPY
- Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells
- (2017) Muzafar A. Macha et al. Oncotarget
- Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials
- (2017) Zhi-qiao Xu et al. BMJ Open
- Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
- (2017) et al. Cancers
- A randomized, double-blind phase II trial of exemestane with or without MM-121 in postmenopausal women with locally advanced or metastatic estrogen receptor-positive (ER+) and/or progesterone receptor-positive (PR+), HER2-negative breast cancer.
- (2017) V. M. Moyo et al. JOURNAL OF CLINICAL ONCOLOGY
- Panitumumab in combination with FEC 100 (5-fluorouracil, epidoxorubicin, cyclophosphamide) followed by docetaxel (T) in patients with operable, triple-negative breast cancer (TNBC): Preliminary results of a multicenter neoadjuvant pilot phase II study.
- (2017) J. Nabholtz et al. JOURNAL OF CLINICAL ONCOLOGY
- HER3 as a Therapeutic Target in Cancer
- (2016) Niki Karachaliou et al. BIODRUGS
- Trastuzumab in the Treatment of Breast Cancer
- (2016) Sofia Maximiano et al. BIODRUGS
- Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer
- (2016) Shruti R. Tiwari et al. BREAST CANCER RESEARCH AND TREATMENT
- Antibody-drug conjugates—an emerging class of cancer treatment
- (2016) Nikolaos Diamantis et al. BRITISH JOURNAL OF CANCER
- The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
- (2016) Jennifer L. Hsu et al. CANCER AND METASTASIS REVIEWS
- Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
- (2016) Meenakshi Hegde et al. JOURNAL OF CLINICAL INVESTIGATION
- Preclinical and clinical studies on afatinib in monotherapy and in combination regimens: Potential impact in colorectal cancer
- (2016) I. De Pauw et al. PHARMACOLOGY & THERAPEUTICS
- Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy
- (2016) Qian Chen et al. Nature Communications
- Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer
- (2016) Abderrahim El Guerrab et al. Oncotarget
- Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes
- (2016) Xiaofeng Dai et al. Journal of Cancer
- Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer
- (2015) Adela Madrid-Paredes et al. BREAST CANCER RESEARCH AND TREATMENT
- Original paper Prognostic value of PIK3CA mutation status, PTEN and androgen receptor expression for metastasis-free survival in HER2-positive breast cancer patients treated with trastuzumab in adjuvant setting
- (2015) Agnieszka Adamczyk et al. POLISH JOURNAL OF PATHOLOGY
- Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status
- (2015) Florence Huguet et al. Targeted Oncology
- Photothermal ablation of bone metastasis of breast cancer using PEGylated multi-walled carbon nanotubes
- (2015) Zhen Lin et al. Scientific Reports
- Role of ErbB Receptors in Cancer Cell Migration and Invasion
- (2015) Aline Appert-Collin et al. Frontiers in Pharmacology
- Near Infrared Photoimmunotherapy Targeting EGFR Positive Triple Negative Breast Cancer: Optimizing the Conjugate-Light Regimen
- (2015) Tadanobu Nagaya et al. PLoS One
- Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
- (2015) Alexandra Canonici et al. Oncotarget
- Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact
- (2014) J. M. Nabholtz et al. ANNALS OF ONCOLOGY
- Role of human epidermal growth factor receptor 2 in gastric cancer: Biological and pharmacological aspects
- (2014) Jan Trøst Jørgensen WORLD JOURNAL OF GASTROENTEROLOGY
- Treatment of HER2-positive breast cancer
- (2013) Maria Cristina Figueroa-Magalhães et al. BREAST
- Oncogenic ERBB3 Mutations in Human Cancers
- (2013) Bijay S. Jaiswal et al. CANCER CELL
- RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector Activation
- (2013) C. Mirschberger et al. CANCER RESEARCH
- HER2 and lung cancer
- (2013) Lorenza Landi et al. Expert Review of Anticancer Therapy
- STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits
- (2013) SEYUNG S. CHUNG et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer
- (2013) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
- (2013) Weiyi Toy et al. NATURE GENETICS
- Targeting triple-negative breast cancer: optimising therapeutic outcomes
- (2012) K. Gelmon et al. ANNALS OF ONCOLOGY
- Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy
- (2012) A. Awada et al. ANNALS OF ONCOLOGY
- A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
- (2012) Nancy U. Lin et al. BREAST CANCER RESEARCH AND TREATMENT
- Targeting the EGFR signaling pathway in cancer therapy
- (2012) Parthasarathy Seshacharyulu et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling
- (2012) Scott Wilkie et al. JOURNAL OF CLINICAL IMMUNOLOGY
- TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
- (2012) Lisa A. Carey et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3
- (2012) C. F. McDonagh et al. MOLECULAR CANCER THERAPEUTICS
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- p95HER2 and Breast Cancer
- (2011) J. Arribas et al. CANCER RESEARCH
- Zalutumumab in head and neck cancer
- (2011) Ulrike Schick et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium
- (2011) J. M. Balko et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
- (2011) J. T. Garrett et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation
- (2010) B. Schoeberl et al. CANCER RESEARCH
- Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
- (2010) Daniel P. Silver et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
- (2010) Kimberly L. Blackwell et al. JOURNAL OF CLINICAL ONCOLOGY
- Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
- (2009) B. Corkery et al. ANNALS OF ONCOLOGY
- Current situation of zalutumumab
- (2009) Fernando Rivera et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer
- (2009) Prithviraj Bose et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Internalization and intracellular sorting of the EGF receptor: a model for understanding the mechanisms of receptor trafficking
- (2009) I. H. Madshus et al. JOURNAL OF CELL SCIENCE
- Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms
- (2009) M Hollmén et al. ONCOGENE
- The Development of HKI‐272 and Related Compounds for the Treatment of Cancer
- (2008) Allan Wissner et al. ARCHIV DER PHARMAZIE
- A Central Role for HER3 in HER2-Amplified Breast Cancer: Implications for Targeted Therapy
- (2008) S. T. Lee-Hoeflich et al. CANCER RESEARCH
- Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
- (2008) P MEDINA et al. CLINICAL THERAPEUTICS
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
- (2008) Cornelia Liedtke et al. JOURNAL OF CLINICAL ONCOLOGY
- Cross-Talk Between the ErbB/HER Family and the Type I Insulin-Like Growth Factor Receptor Signaling Pathway in Breast Cancer
- (2008) Quanri Jin et al. JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started